Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. https://t.co/eemXpnmcZt
RT @jitcancer: #JITC Research: Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or un…
RT @__ice9: Relatedly: I still see strong indications that an anti-IL-8 mAb would likely be helpful in treating this disease. Currently,…
Relatedly: I still see strong indications that an anti-IL-8 mAb would likely be helpful in treating this disease. Currently, there are none on the market. https://t.co/7wiDo6gIzF https://t.co/DMwvrRX923 https://t.co/ORgufq1oRH https://t.co/4lnSK9cF0n
#JITC Research: Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors https://t.co/Q6nfrRKPla https://t.co/zGCjFcGuxH
RT @DrKateLurain: Great work from @mbilusic and a whole host of former #nih_heme_onc_fellows @NCIResearchCtr @gulleyj1 @ChrisHeery @julieco…
RT @NCICCR_MOS: The 1st study to evaluate HuMax-IL8, a #monoclonal #antibody inhibiting the IL-8 known to promote tumor progression, in can…
RT @NCICCR_MOS: The 1st study to evaluate HuMax-IL8, a #monoclonal #antibody inhibiting the IL-8 known to promote tumor progression, in can…
RT @NCICCR_MOS: The 1st study to evaluate HuMax-IL8, a #monoclonal #antibody inhibiting the IL-8 known to promote tumor progression, in can…
The 1st study to evaluate HuMax-IL8, a #monoclonal #antibody inhibiting the IL-8 known to promote tumor progression, in cancer patients shows it to be safe & well tolerated. 8 paper coauthors are #NIH_Heme_Onc_Fellow alumni, incl. 1st author @mbilusic
RT @DrKateLurain: Great work from @mbilusic and a whole host of former #nih_heme_onc_fellows @NCIResearchCtr @gulleyj1 @ChrisHeery @julieco…
Great work from @mbilusic and a whole host of former #nih_heme_onc_fellows @NCIResearchCtr @gulleyj1 @ChrisHeery @juliecollinsmd @Dr_RaviMadan @DrGattiMays @FatimaKarzai
RT @gulleyj1: Proud to be on this team doing a first in cancer patients trial of this anti-IL8 antibody. @mbilusic @Dr_RaviMadan https://t.…
RT @sitcancer: New #JITC Research: Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic o…
RT @gulleyj1: Proud to be on this team doing a first in cancer patients trial of this anti-IL8 antibody. @mbilusic @Dr_RaviMadan https://t.…
RT @gulleyj1: Proud to be on this team doing a first in cancer patients trial of this anti-IL8 antibody. @mbilusic @Dr_RaviMadan https://t.…
RT @gulleyj1: Proud to be on this team doing a first in cancer patients trial of this anti-IL8 antibody. @mbilusic @Dr_RaviMadan https://t.…
Proud to be on this team doing a first in cancer patients trial of this anti-IL8 antibody. @mbilusic @Dr_RaviMadan
RT @sitcancer: New #JITC Research: Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic o…
New #JITC Research: Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors https://t.co/dORrcvucOO https://t.co/fWCeE75k7I
RT @gulleyj1: Check out Dr. @mbilusic, Dr. @ChrisHeery and team's anti-IL8 clinical trial just published in #JITC. https://t.co/DPQIVz1HVF…
RT @gulleyj1: Check out Dr. @mbilusic, Dr. @ChrisHeery and team's anti-IL8 clinical trial just published in #JITC. https://t.co/DPQIVz1HVF…
RT @Dr_RaviMadan: #cytokines are the exciting next frontier of #immunotherapy. Looking forward to incorporating #immunocytokines into our…
RT @Dr_RaviMadan: #cytokines are the exciting next frontier of #immunotherapy. Looking forward to incorporating #immunocytokines into our…
RT @gulleyj1: Check out Dr. @mbilusic, Dr. @ChrisHeery and team's anti-IL8 clinical trial just published in #JITC. https://t.co/DPQIVz1HVF…
RT @Dr_RaviMadan: #cytokines are the exciting next frontier of #immunotherapy. Looking forward to incorporating #immunocytokines into our…
RT @Dr_RaviMadan: #cytokines are the exciting next frontier of #immunotherapy. Looking forward to incorporating #immunocytokines into our…
RT @Dr_RaviMadan: #cytokines are the exciting next frontier of #immunotherapy. Looking forward to incorporating #immunocytokines into our…
RT @gulleyj1: Check out Dr. @mbilusic, Dr. @ChrisHeery and team's anti-IL8 clinical trial just published in #JITC. https://t.co/DPQIVz1HVF…
RT @Dr_RaviMadan: #cytokines are the exciting next frontier of #immunotherapy. Looking forward to incorporating #immunocytokines into our…
RT @Dr_RaviMadan: #cytokines are the exciting next frontier of #immunotherapy. Looking forward to incorporating #immunocytokines into our…
RT @gulleyj1: Check out Dr. @mbilusic, Dr. @ChrisHeery and team's anti-IL8 clinical trial just published in #JITC. https://t.co/DPQIVz1HVF…
RT @Dr_RaviMadan: #cytokines are the exciting next frontier of #immunotherapy. Looking forward to incorporating #immunocytokines into our…
RT @Dr_RaviMadan: #cytokines are the exciting next frontier of #immunotherapy. Looking forward to incorporating #immunocytokines into our…
RT @gulleyj1: Check out Dr. @mbilusic, Dr. @ChrisHeery and team's anti-IL8 clinical trial just published in #JITC. https://t.co/DPQIVz1HVF…
#cytokines are the exciting next frontier of #immunotherapy. Looking forward to incorporating #immunocytokines into our #ProstateCancer Studies @thenci.
RT @gulleyj1: Check out Dr. @mbilusic, Dr. @ChrisHeery and team's anti-IL8 clinical trial just published in #JITC. https://t.co/DPQIVz1HVF…
RT @gulleyj1: Check out Dr. @mbilusic, Dr. @ChrisHeery and team's anti-IL8 clinical trial just published in #JITC. https://t.co/DPQIVz1HVF…
RT @gulleyj1: Check out Dr. @mbilusic, Dr. @ChrisHeery and team's anti-IL8 clinical trial just published in #JITC. https://t.co/DPQIVz1HVF…
RT @gulleyj1: Check out Dr. @mbilusic, Dr. @ChrisHeery and team's anti-IL8 clinical trial just published in #JITC. https://t.co/DPQIVz1HVF…
Check out Dr. @mbilusic, Dr. @ChrisHeery and team's anti-IL8 clinical trial just published in #JITC. https://t.co/DPQIVz1HVF https://t.co/MWoa1C7TRt